Quantcast

Latest Ketones Stories

2014-05-06 16:26:53

CARDIFF, Calif., May 6, 2014 /PRNewswire/ -- NI Research has released the May issue of NeuroPerspective, which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the companies developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine, and has been further invigorated by the success of Naurex's GlyX-13 in clinical testing. As NeuroPerspective publisher Harry...

2014-05-06 04:23:32

The Jeffrey Epstein VI Foundation and the Melanoma Research Alliance put their support behind the much needed Sunscreen Innovation Act. NEW YORK, May 6, 2014 /PRNewswire/ -- Sunscreens are long overdue for a makeover: in fact active ingredients in US sunscreens haven't been updated for fifteen years, despite dermatologist and oncologist warnings that US sunscreens are not effective enough. Today, the Jeffrey Epstein VI Foundation, an active supporter of the Melanoma Research...

2014-04-30 12:30:02

Patent Protection for KP511 Extends KemPharm's Intellectual Property Estate for Leading Franchise of Abuse-Deterrent Opioid Medications CORALVILLE, Iowa, April 30, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Benzoic...

2014-04-30 08:33:23

Data from Clinical Drug-liking Studies Also to be Presented at APS Today STAMFORD, Conn., April 30, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) seeking authorization to market a once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate...

2014-04-30 08:32:53

GeneSight® Analgesic Test Now Includes 22 Opioids and Non-opioid Pain Medications MASON, Ohio, April 30, 2014 /PRNewswire/ -- Assurex Health, Inc. today announced a significant expansion of its GeneSight® Analgesic test. The expanded test gives clinicians a multi-gene pharmacogenomics tool to guide medication decisions for patients with acute or chronic pain using patients' own genetic profiles to help determine their potential response to 22 medications across four relevant...

2014-04-30 08:32:05

FIRST® - Vancomycin compounding kits make pharmacy compounding easier WOBURN, Mass., April 30, 2014 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST(® )- Vancomycin oral solution compounding kits. With FIRST(®) - Vancomycin, the oral solution is compounded within a minute by adding the pre-measured white grape flavored solution to the pre-weighed vancomycin hydrochloride powder bottle and shaking it. The pleasant white grape flavor helps mask the typical...

2014-04-29 20:26:48

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: The World Market for Pain Management Drugs and Deviceshttp://www.reportbuyer.com/pharma_healthcare/healthcare/world_market_pain_management_drugs_devices.html This study encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to...

2014-04-29 12:33:30

STAMFORD, Conn., April 29, 2014 /PRNewswire/ -- Purdue Pharma L.P. will present results from a number of research studies at the American Pain Society (APS) 33(rd) Annual Scientific Meeting, April 30-May 3, 2014, in Tampa, Fla. Following is a schedule of select poster presentations: Authors Date / Time Title...

2014-04-29 08:35:55

WAYNE, Pa., April 29, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that its first quarter financial results will be released on Tuesday, May 13, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the company's financial and operating results and provide a general business update. http://photos.prnewswire.com/prnvar/20140219/NY67493LOGO Interested parties may...

2014-04-29 08:34:35

Recently Released ACC/AHA Practice Guidelines Reinforce Unmet Need MENLO PARK, Calif., April 29, 2014 /PRNewswire/ -- Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin. Tecarfarin is positioned to be the only oral anticoagulant (OAC) therapy for patients with prosthetic heart valves (PHV) specifically identified in the label. In addition, the...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.